Article Highlights CanREValue Collaboration for RWE
A recent article published in BMJ highlights efforts by the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, [...]
How Artificial Intelligence and Real World Data Can Improve the Management of Type 2 Diabetes: A Case Study
See how Veradigm, a business unit of Allscripts focused on generating data-driven healthcare insights using EHR data applied artificial intelligence to EHRs to improve therapeutic management of patients with concordant comorbidities who are living with type 2 diabetes.
Using Innovative Data Analytics for Market Access
Dr. Patti Peeples, CEO of HealthEconomics.com, sat down with Walter Bouwmeester, Real-World Evidence and Data Analytics Lead in Europe, to discuss the use of data analytics to support multidimensional health economics and outcomes research (HEOR) in Europe.
Closing Gaps in Real-World Evidence through Data Linkage
Interview with Dr. Kevin Haynes, Principal Scientist, HealthCore-NERI. Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Kevin Haynes, [...]
Storytelling, Giving Back, and Legacy: How AESARA is Doing it Differently
A market access agency. https://aesara.com A few months ago, I was sipping my morning coffee and perusing the health economics [...]
Changing the Clinical Trial Paradigm for Rare and Orphan (R&O) Diseases using Real-World Evidence
Interview with Flora Sandra Siami, MPH. Vice President of Clinical Research, Regulatory Affairs, and Quality Assurance at HealthCore-NERI. Dr. Patti [...]
Real-world evidence and value-based contracting – swipe left or swipe right?
As biopharma makes the shift toward a personalized healthcare system, it is also transitioning towards a pipeline full of innovative, [...]
Advancing Real-World Evidence with Pragmatic Clinical Trials: Interview with Dr. Joseph Singer, Chief Medical Officer of HealthCore-NERI
Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Joseph Singer, CMO of HealthCore-NERI, to discuss how pragmatic clinical [...]
Key Elements of a Real-World Evidence Generation Plan: Integration of Product Support Activities
Shelby CormanPharmerit International Real-world evidence is a key component of value demonstration for pharmaceuticals, diagnostic agents, and medical [...]
Benchmarking Survey: Can we reduce procurement time in HEOR & RWE?
As healthcare moves towards an increased focus on outcomes and value, health economics & outcomes research (HEOR) and real-world evidence [...]
Building Trust In Real World Evidence – From Regulators To Patients
Bill Fox Chief Strategist for Global Healthcare, Life Sciences, and Insurance MarkLogic In a climate of growing consumer [...]
Who Are the Real Change-Agents in Pharma Market Access? The Growing Role of Value Demonstration
Would you believe it if I said that in a few years, the term "HEOR" may go the way of man-buns [...]
Artificial Intelligence for Real-World Evidence
Costas Boussios, VP of Data Science, OM1 Richard Gliklich, CEO, OM1 As artificial intelligence (AI) and Big Data are lauded [...]
Big Ideas for Big Data Analytics in Real-World Evidence: Insights from Dr. Rich Gliklich, CEO of OM1
Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Rich Gliklich, CEO of OM1, to discuss how big [...]
Industry Groups Challenge Readiness of ICER’s Value Framework
Healthcare is all about making decisions. Who to treat? When to treat? How to treat? How long to treat? How [...]
A Brief History of Diabetes Simulation Modelling and the Mt Hood Challenge
Why is a diabetes and economics simulation modelling conference named after a mountain? Back in 1999, two groups who developed [...]
Schizophrenia caregivers – realizing the impact
Schizophrenia is a debilitating condition that makes it difficult for patients to perform routine daily tasks or hold a job. [...]
The New Decision Analysis Guidance from ISPOR: How it is Like HouseHunters
'Multiple criteria decision analysis' is a crummy name for a great concept (aren't all big decisions analyzed using multiple criteria?). [...]
Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.
Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]
How Should Health Care Providers Measure and Market the “Value” of their Services?
John Schneider, Ph.D There was a time when we did not spend a lot of time worrying about [...]
Removing Bias from HEOR: Standardizing the Costs of Adverse Events
By Jim Davis What are the total costs of prescribing a particular drug? At its core, all health [...]
21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety
By Jim Davis As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. [...]
Health Informatics, A Fast-Growing Field and a Crucial Skill-Set: An Interview with Dr. Patrick Casimir
What is Health Informatics? What discipline combines information technology, programming, analytical skills, communication abilities, and a deep desire to improve [...]
Sneak Peak at Pharma Industry Survey on Observational Research: Progress not Perfection
By Jeff Trotter, President, Continuum Clinical I write this blog the evening before giving a presentation on observational research to [...]
WHEN 1+1=3: HOW ELECTRONIC HEALTH RECORDS AND CLAIMS CAN BE USED SYNERGISTICALLY
Sponsored blog posting by DaVita Clinical Research. 1. Combining Drug Development with Real-World Data Analytics DaVita Clinical Research® (DCR®), a [...]
